Close Menu

NEW YORK (GenomeWeb) – Caribou Biosciences announced today that it has signed a deal under which it will use its CRISPR/Cas 9 gene-editing technology for the discovery and validation of new drug targets for Novartis.

Concurrent with the agreement, Novartis has also taken an undisclosed equity stake in Caribou through a Series A investment round.

Caribou will receive research funding from Novartis under the one-year term of the agreement, and it has also provided Novartis with an option to non-exclusively license its CRISPR/Cas 9 platform for research applications.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.